Liberum develops advanced cell-free systems and experimental platforms for protein discovery, directed evolution and vaccine manufacturing, compressing the distance between a biological idea and the data needed to act on it.
Sequence generation is becoming abundant. The harder problem is converting those sequences into physical molecules and meaningful measurements quickly enough to keep pace. Our cell-free systems are built to shorten that path while remaining grounded in the biology of their cell-based counterparts.
The future of protein engineering is not just better prediction. It is tighter coupling between design and experiment.
Liberum builds the tools that make those loops faster, from cell-free reagents researchers can use themselves to integrated discovery and rapid manufacturing programs.
Our work is concentrated in three areas where faster expression and better experimental feedback can materially change what scientists are able to do.
We combine directed evolution, targeted sequence diversity, rapid expression and screening to improve affinity and generate standardized sequence-to-phenotype data across iterative rounds. The aim is not simply more variants, it is more informative experiments and better evidence for where to search next.
Talk to us about affinity maturation →Our cell-free technologies span antibody fragments through full-length IgG. Researchers can access reagents for VHs, VHHs, scFvs and other binders through cell-free.com. Fynd applies our mammalian systems to rapid production of full-length, glycosylated IgGs for earlier physical testing.
We develop cell-free approaches for producing vaccine antigens and virus-like particles on compressed timelines, with an emphasis on systems that can be reconfigured rapidly as the biological target changes. That flexibility is particularly relevant to personalized medicine, emerging pathogens and pandemic response.
Talk to us about vaccine antigens →Our reagent storefront for researchers working with cell-free protein expression, including binder-focused workflows for VHs, VHHs and scFvs.
Explore cell-free reagents →A focused antibody application of Liberum's mammalian cell-free technology, designed to help teams move promising sequences into full-length, glycosylated IgG earlier in discovery.
Visit Fynd →Our systems are developed with their cell-based counterparts in view. We use comparability to identify what is lost, altered or preserved outside the intact cell, then use that evidence to guide the next generation of the platform.
If protein expression, screening throughput, variant generation or manufacturing is slowing the program down, we want to understand where the constraint really is.